A new study shows that immunity after a COVID-19 booster lasts much longer than the primary series alone. These findings are among other, sometimes 'unintuitive,' revelations of how factors like age, ...
Updated vaccines by Pfizer (NYSE:PFE)/BioNTech (NASDAQ ... or older get the updated vaccine if they haven’t gotten a booster recently. The FDA is also in the process of reviewing an updated ...
The updated adjuvanted ... For mRNA vaccines, such as Pfizer-BioNTech and Moderna, booster doses are recommended based on evidence showing increased immunity post-booster, which is considered ...
People who got the COVID-19 booster had stronger protection against the virus that causes the disease compared to people who ...
Vaccine availability is on a first-come, first-served basis and while supplies last. Updated bivalent Pfizer-BioNTech and Moderna COVID-19 vaccines and boosters will be available at the clinics. The ...
April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the ...
COVID vaccine booster shots were rolled out, and about 40 percent of US adults said they did not plan on getting a booster.
Just 15 percent of Americans five and older got the free updated booster. Will they pay Pfizer’s and Moderna’s prices for the next one? Lynch recently represented the NFL in a racial ...
Representatives for Pfizer and BioNTech did not immediately respond to requests for comment. Moderna accused Pfizer and BioNTech's vaccine of violating its patent rights in messenger-RNA ...
Thinking about getting a spring-time booster shot? A new study coming out of York University’s Centre for Disease Modelling in the Faculty of Science shows that immunity after a COVID-19 booster lasts ...
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents ...
The lawsuit adds to a web of high-stakes U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including a case brought by Moderna ...